このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

AMLのHSCT後のメンテナンスとしてのイボシデニブ

2026年10月2日 更新者:Amir Fathi、Massachusetts General Hospital

同種幹細胞移植後のIDH1変異型急性骨髄性白血病に対する維持療法としてイボシデニブを使用したIDH1阻害のランダム化プラセボ対照第2相試験

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).

調査の概要

詳細な説明

This is a prospective, placebo-controlled, randomized, single-blinded, multi-center, phase II study of the mutant IDH1 inhibitor, ivosidenib, compared to placebo in participants with AML after HCT. This study is examining whether or not ivosidenib is beneficial as an agent to prevent the relapse of IDH1-mutated acute myeloid leukemia after hematopoietic stem cell transplantation. The U.S. Food and Drug Administration (FDA) has not approved ivosidenib for this indication following HCT but it has been approved for other uses.

The research study procedures include screening for eligibility and study treatment including evaluations and follow-up. The HCT and any standard treatment before and after the HCT is standard of care.

The estimated length of participation in the study is 3.5 years from screening to the end of planned follow-up, including up to 24 months of study treatment. After the 24-month period, participants are followed for up to 12 additional months. It is expected that about 75 people will take part in this research study.

Servier, a pharmaceutical company, is supporting this research study by providing ivosidenib/placebo and funding for research activities.

研究の種類

介入

入学 (推定)

75

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 募集
        • Emory University Hospital
        • 主任研究者:
          • Amelia Langston, MD
        • コンタクト:
    • Kansas
      • Kansas City、Kansas、アメリカ、66160
        • 募集
        • Kansas University Medical Center
        • 主任研究者:
          • Sunil Abhyankar, MD
        • コンタクト:
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • 募集
        • Massachusetts General Hospital
        • コンタクト:
        • 主任研究者:
          • Amir Fathi, MD
      • Boston、Massachusetts、アメリカ、02115
        • 募集
        • Dana Farber Cancer Institute
        • コンタクト:
        • 主任研究者:
          • Robert Soiffer, MD
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • 募集
        • Ohio State University Wexner Medical Center- James Cancer Hospital
        • コンタクト:
        • 主任研究者:
          • Jiasheng Wang, MD
    • Utah
      • Salt Lake City、Utah、アメリカ、84112
        • 募集
        • Huntsman Cancer Institute, University of Utah
        • 主任研究者:
          • Sagar Patel, MD
        • コンタクト:
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • 募集
        • Froedtert Hospital & the Medical College of Wisconsin
        • コンタクト:
          • Sameem Abedin, MD
          • 電話番号:414-805-4600
          • メール:sabedin@mcw.edu
        • 主任研究者:
          • Sameem Abedin, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Pathologically confirmed diagnosis of IDH1(R132)-mutant acute myeloid leukemia (AML). IDH1 mutations could have been detected by any mutational technique at any prior point including at diagnosis or remission.

  • Between the ages of 18 and 75 years

  • Will undergo allogeneic hematopoietic stem cell transplantation (HSCT) for their malignancy. Conditioning may be either conventional myeloablative (MAC) or reduced intensity conditioning (RIC). There will be no restrictions on type of graft source.

  • ECOG performance status ≤ 2

  • Participants must have normal organ and marrow function as defined below:

    • Absolute neutrophil count ≥ 1000/µL without growth factor support (e.g. GCSF) in the previous 7 days.
    • Platelet count ≥ 50,000/µL without transfusional support in the previous 7 days.
    • AST (SGOT), ALT (SGPT) and Alkaline phosphatase < 3x institutional upper limit of normal (ULN)
    • Direct bilirubin < 2.0 mg/dL
    • Calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula)
  • LVEF must be equal to or greater than 40%, as measured by MUGA scan or echocardiogram

  • Female patients of childbearing potential must have a negative pregnancy test

  • The effects of ivosidenib on the developing human fetus are unknown. For this reason female participants of child-bearing potential and male participants must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during the entire study treatment period and through 90 days after the last dose of treatment

  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Prior allogeneic hematopoietic stem cell transplants.

  • Morphologically relapsed or refractory disease, as assessed by bone marrow aspirate and biopsy performed within 42 days prior to study entry

  • History of other malignancy(ies) unless

    • the participant has been disease-free for at least 5 years and is deemed by the investigator to be at low risk of recurrence of that malignancy, or
    • the only prior malignancy was cervical cancer in situ and/or basal cell or squamous cell carcinoma of the skin
  • Known diagnosis of active hepatitis B or hepatitis C

  • Current or history of congestive heart failure New York Heart Association (NHYA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (LVEF < 40%, as measured by MUGA scan or echocardiogram)

  • Current or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndrome

  • QTc interval (i.e., Friderica's correction [QTcF]) ≥ 450 ms or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) at screening

  • Uncontrolled intercurrent illness that would limit compliance with study requirements.

Post-transplantation Pre-Treatment Criteria Treatment may begin at any time between day 45 and day 90 following stem cell transplantation.

However, at time of treatment start, it must be ensured that:

  • The patient has continued willingness and interest in participating in the study.

  • There is no systemic infection requiring IV antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection

  • Chimerism studies reveal that ≥ 70% of blood or bone marrow cells, or of the CD33 expressing fraction, are of donor origin,

  • There is no acute graft versus host disease (GVHD), requiring an equivalent dose of ≥ 0.5mg/kg/day of prednisone within one week of starting ivosidenib / placebo, or have escalation of systemic immunosuppression in terms of increase of corticosteroids or addition of new agent/modality within two weeks of starting ivosidenib / placebo.

  • For prophylaxis for GVHD, agents that are permitted for administration on study:

    • Tacrolimus
    • Cyclosporine
    • Sirolimus
    • Cyclophosphamide
    • Mycophenolate Mofetil
    • Methotrexate
    • ATG
    • Ruxolitinib
    • Vedolizumab
    • As standards of care may change, any other prophylactic agents used should be discussed with the PI.
  • Investigational agents, defined as not approved for any indication, are forbidden unless the participant comes off study.

    • Agents used to treat GVHD that are permitted for administration on study:

    • Any agent used in prophylaxis may be continued (see list above)

      • Ruxolitinib
      • Etanarcept
      • ATG
      • Belumosidil
      • Axatilimab
      • Rituximab
      • Fecal microbiota transplantation
      • Alpha1-Antitrypsin
      • Pregnyl
      • Extracorporal photopheresis (ECP)
    • As standards of care may change, any other treatment agents used should be discussed with the PI.

    • Investigational agents, defined as not approved for any indication, are forbidden unless the participant comes off study.

  • There is no evidence of relapsed/recurrent/residual disease.

  • Prior to the start of ivosidenib / placebo administration, the participant must have adequate hematological function, defined as:

    • ANC ≥ 1000/µL
    • Platelets ≥ 50,000/µL

and adequate organ function defined as

  • Direct bilirubin level < 2.0 mg/dL
  • AST (SGOT), ALT (SGPT) and Alkaline phosphatase < 3x institutional upper limit of normal (ULN)
  • No presence of congestive heart failure, defined by New York Heart Association (NHYA) criteria as class 3 or 4
  • Calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Ivosidenib

After screening and standard of care hematopoietic stem cell transplantation (HCT) and any standard treatment before and after the HSCT, Ivosidenib will be given orally (PO) once daily (QD) in 28-day continuous cycles. Ivosidenib is administered at a pre-determined dose with a goal of 500mg daily. Participants begin study treatment 45 to 90 days after HCT, and treatment will continue for up to 24 months. Study visits and assessments occur throughout study treatment and in follow-up. After the 24-month treatment period, participants are followed for up to 12 additional months.

Ivosidenib tablets are supplied as 50 mg, 200 mg, and 250 mg strengths, to be taken orally.

他の名前:
  • AG-120
  • S95031
プラセボコンパレーター:Placebo

After screening and standard of care hematopoietic stem cell transplantation (HCT) and any standard treatment before and after the HSCT, Placebo will be given orally (PO) once daily (QD) in 28-day continuous cycles. Participants begin study treatment (placebo) 45 to 90 days after HCT, and treatment (placebo) will continue for up to 24 months. Study visits and assessments occur throughout study treatment period and in follow-up. After the 24-month treatment period, participants are followed for up to 12 additional months.

Placebo tablets are taken orally.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Relapse-Free Survival (RFS)
時間枠:Time of randomization to 24 months post-randomization, death, or disease relapse whichever occurs first.

Relapse-Free Survival is defined as the time from randomization following transplant to disease relapse or death due to any cause, whichever occurs first. Participants alive without relapse are censored at the date of last seen alive. The primary analysis will be performed using the Kaplan-Meier method with log-rank test.

Time of randomization to 24 months post-randomization, death, or disease relapse whichever occurs first.

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Survival (OS)
時間枠:Up to 39 months (Day of HCT (Day -90 to Day -45) through 24 months of treatment period and 12 months of follow-up)

Overall Survival is defined as the time from stem cell transplant (HCT) to the date of death due to any cause. Participants who are alive at the analysis / cutoff date will be censored at the last contact date. Baseline characteristics will be reported descriptively and compared using Fisher's exact test, χ2 test or Wilcoxon rank-sum test, as appropriate. The Kaplan-Meier method will be used to estimate OS; Multivariable Cox regression analysis will be used for OS analysis.

Up to 39 months (Day of HCT (Day -90 to Day -45) through 24 months of treatment period and 12 months of follow-up)
Incidence of treatment related adverse events (TRAE)
時間枠:Up to 25 months (Day 1 of study drug treatment for up to 24 months of treatment plus 30 days post final dose)

TRAEs will be graded and categorized using the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5. Baseline characteristics will be reported descriptively and compared using Fisher's exact test, χ2 test or Wilcoxon rank-sum test, as appropriate.

Up to 25 months (Day 1 of study drug treatment for up to 24 months of treatment plus 30 days post final dose)
Cumulative incidence of acute and chronic Graft vs. Host Disease (GVHD)
時間枠:Up to 36 months (Start of study treatment for 24 months, plus 12 months of follow-up)

Chronic GVHD will be assessed as per the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Cumulative incidence of acute and chronic GVHD (grade II-IV acute GVHD, grade III-IV acute GVHD, chronic GVHD, steroid-requiring chronic GVHD) will be estimated in the context of a competing risks framework. Gray test and Gray regression analysis will be used for comparison of cumulative incidence of GVHD.

Up to 36 months (Start of study treatment for 24 months, plus 12 months of follow-up)
Measurable Residual Risease (MRD)
時間枠:Pre-transplant screening (up to Day -132) through 12 months of study treatment period, for up to 16.5 months.

MRD will be assessed by Next Generation Sequencing (NGS) testing at screening before stem cell transplant, post-transplant before initiation of study treatment, and at the start of study treatment cycles 6 and 12.

Pre-transplant screening (up to Day -132) through 12 months of study treatment period, for up to 16.5 months.
Cumulative incidence rate of relapse of acute myeloid leukemia (AML)
時間枠:From stem cell transplant through 12 months treatment period or relapse, whichever is first., up to 15 months.

Disease assessment (relapse) will be based on modified IWG criteria or other appropriate response criteria for the malignancy being studied. Cumulative incidence of relapse of AML will be estimated in the context of a competing risks framework using the Gray test and Fine and Gray regression analysis.

From stem cell transplant through 12 months treatment period or relapse, whichever is first., up to 15 months.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • 主任研究者:Amir T Fathi, MD、Massachusetts General Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月16日

一次修了 (推定)

2028年1月1日

研究の完了 (推定)

2030年1月1日

試験登録日

最初に提出

2024年11月23日

QC基準を満たした最初の提出物

2024年11月23日

最初の投稿 (実際)

2024年11月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [Amir T. Fathi, M.D. afathi@mgh.harvard.edu ]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 共有時間枠

Data can be shared no earlier than 1 year following the date of publication

IPD 共有アクセス基準

Contact the Partners Innovations team at http://www.partners.org/innovation

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する